- Home
- RDIB vs PLX Comparison
RDIB vs PLX Comparison
Compare RDIB & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- PLX
- Stock Information
- Founded
- RDIB 1937
- PLX 1993
- Country
- RDIB United States
- PLX Israel
- Employees
- RDIB N/A
- PLX N/A
- Industry
- RDIB Movies/Entertainment
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDIB Consumer Discretionary
- PLX Health Care
- Exchange
- RDIB Nasdaq
- PLX Nasdaq
- Market Cap
- RDIB 140.2M
- PLX 160.2M
- IPO Year
- RDIB N/A
- PLX 1998
- Fundamental
- Price
- RDIB $6.86
- PLX $2.39
- Analyst Decision
- RDIB
- PLX Strong Buy
- Analyst Count
- RDIB 0
- PLX 1
- Target Price
- RDIB N/A
- PLX $15.00
- AVG Volume (30 Days)
- RDIB 937.0
- PLX 634.9K
- Earning Date
- RDIB 03-28-2025
- PLX 03-13-2025
- Dividend Yield
- RDIB N/A
- PLX N/A
- EPS Growth
- RDIB N/A
- PLX N/A
- EPS
- RDIB N/A
- PLX N/A
- Revenue
- RDIB $197,270,000.00
- PLX $45,667,000.00
- Revenue This Year
- RDIB N/A
- PLX N/A
- Revenue Next Year
- RDIB $18.29
- PLX $63.84
- P/E Ratio
- RDIB N/A
- PLX N/A
- Revenue Growth
- RDIB N/A
- PLX N/A
- 52 Week Low
- RDIB $5.78
- PLX $0.82
- 52 Week High
- RDIB $21.34
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- RDIB 50.90
- PLX 48.43
- Support Level
- RDIB $6.83
- PLX $2.43
- Resistance Level
- RDIB $7.48
- PLX $2.73
- Average True Range (ATR)
- RDIB 0.22
- PLX 0.13
- MACD
- RDIB 0.09
- PLX -0.04
- Stochastic Oscillator
- RDIB 58.90
- PLX 13.95
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.